Cargando…

Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2

INTRODUCTION: Since March of 2020, over 210 million SARS-CoV-2 cases have been reported and roughly five billion doses of a SARS-CoV-2 vaccine have been delivered. The rise of the more infectious delta variant has recently indicated the value of reinstating previously relaxed non-pharmacological and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pettit, Rowland, Peng, Bo, Yu, Patrick, Matos, Peter G., Greninger, Alexander L., McCashin, Julie, Amos, Christopher Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475973/
https://www.ncbi.nlm.nih.gov/pubmed/34580677
http://dx.doi.org/10.1101/2021.09.17.21263723
_version_ 1784575503664939008
author Pettit, Rowland
Peng, Bo
Yu, Patrick
Matos, Peter G.
Greninger, Alexander L.
McCashin, Julie
Amos, Christopher Ian
author_facet Pettit, Rowland
Peng, Bo
Yu, Patrick
Matos, Peter G.
Greninger, Alexander L.
McCashin, Julie
Amos, Christopher Ian
author_sort Pettit, Rowland
collection PubMed
description INTRODUCTION: Since March of 2020, over 210 million SARS-CoV-2 cases have been reported and roughly five billion doses of a SARS-CoV-2 vaccine have been delivered. The rise of the more infectious delta variant has recently indicated the value of reinstating previously relaxed non-pharmacological and test-driven preventative measures. These efforts have been met with resistance, due, in part, to a lack of site-specific quantitative evidence which can justify their value. As vaccination rates continue to increase, a gap in knowledge exists regarding appropriate thresholds for escalation and de-escalation of COVID-19 preventative measures. METHODS: We conducted a series of simulation experiments, trialing the spread of SARS-CoV-2 virus in a hypothesized working environment that is subject to COVID-19 infections from the surrounding community. We established cohorts of individuals who would, in simulation, work together for a set period of time. With these cohorts, we tested the rates of workplace and community acquired infections based on applied isolation strategies, community infection rates (CIR), scales of testing, non-pharmaceutical interventions, variant predominance’s and testing strategies, vaccination coverages, and vaccination efficacies of the members included. Permuting through each combination of these variables, we estimated expected case counts for 33,462 unique workplace scenarios. RESULTS: When the CIR is 5 new confirmed cases per 100,000 or fewer, and at 50% of the workforce is vaccinated with a 95% efficacious vaccine, then testing daily with an antigen-based or PCR based test in only unvaccinated workers will result in less than one infection through 4,800 person weeks. When the community infection rate per 100,000 persons is less than or equal to 60, and the vaccination coverage of the workforce is 100% with 95% vaccine efficacy then no masking or routine testing + isolation strategies are needed to prevent workplace acquired infections regardless of variant predominance. Identifying and isolating workers with antigen-based SARS-CoV-2 testing methods results in the same or fewer workplace acquired infections than testing with polymerase chain reaction (PCR) methods. CONCLUSIONS: Specific scenarios exist in which preventative measures taken to prevent SARS-CoV-2 spread, including masking, and testing plus isolation strategies can safely be relaxed. Further, efficacious testing with quarantine strategies exist for implementation in only unvaccinated cohorts in a workplace. Due to shorter turnaround time, antigen-based testing with lower sensitivity is more effective than PCR testing with higher sensitivities in comparable testing strategies. The general reference interactive heatmap we provide can be used for site specific, immediate, parameter-based case count predictions to inform appropriate institutional policy making.
format Online
Article
Text
id pubmed-8475973
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-84759732021-09-28 Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2 Pettit, Rowland Peng, Bo Yu, Patrick Matos, Peter G. Greninger, Alexander L. McCashin, Julie Amos, Christopher Ian medRxiv Article INTRODUCTION: Since March of 2020, over 210 million SARS-CoV-2 cases have been reported and roughly five billion doses of a SARS-CoV-2 vaccine have been delivered. The rise of the more infectious delta variant has recently indicated the value of reinstating previously relaxed non-pharmacological and test-driven preventative measures. These efforts have been met with resistance, due, in part, to a lack of site-specific quantitative evidence which can justify their value. As vaccination rates continue to increase, a gap in knowledge exists regarding appropriate thresholds for escalation and de-escalation of COVID-19 preventative measures. METHODS: We conducted a series of simulation experiments, trialing the spread of SARS-CoV-2 virus in a hypothesized working environment that is subject to COVID-19 infections from the surrounding community. We established cohorts of individuals who would, in simulation, work together for a set period of time. With these cohorts, we tested the rates of workplace and community acquired infections based on applied isolation strategies, community infection rates (CIR), scales of testing, non-pharmaceutical interventions, variant predominance’s and testing strategies, vaccination coverages, and vaccination efficacies of the members included. Permuting through each combination of these variables, we estimated expected case counts for 33,462 unique workplace scenarios. RESULTS: When the CIR is 5 new confirmed cases per 100,000 or fewer, and at 50% of the workforce is vaccinated with a 95% efficacious vaccine, then testing daily with an antigen-based or PCR based test in only unvaccinated workers will result in less than one infection through 4,800 person weeks. When the community infection rate per 100,000 persons is less than or equal to 60, and the vaccination coverage of the workforce is 100% with 95% vaccine efficacy then no masking or routine testing + isolation strategies are needed to prevent workplace acquired infections regardless of variant predominance. Identifying and isolating workers with antigen-based SARS-CoV-2 testing methods results in the same or fewer workplace acquired infections than testing with polymerase chain reaction (PCR) methods. CONCLUSIONS: Specific scenarios exist in which preventative measures taken to prevent SARS-CoV-2 spread, including masking, and testing plus isolation strategies can safely be relaxed. Further, efficacious testing with quarantine strategies exist for implementation in only unvaccinated cohorts in a workplace. Due to shorter turnaround time, antigen-based testing with lower sensitivity is more effective than PCR testing with higher sensitivities in comparable testing strategies. The general reference interactive heatmap we provide can be used for site specific, immediate, parameter-based case count predictions to inform appropriate institutional policy making. Cold Spring Harbor Laboratory 2021-09-21 /pmc/articles/PMC8475973/ /pubmed/34580677 http://dx.doi.org/10.1101/2021.09.17.21263723 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Pettit, Rowland
Peng, Bo
Yu, Patrick
Matos, Peter G.
Greninger, Alexander L.
McCashin, Julie
Amos, Christopher Ian
Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2
title Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2
title_full Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2
title_fullStr Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2
title_full_unstemmed Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2
title_short Optimized Post-Vaccination Strategies and Preventative Measures for SARS-CoV-2
title_sort optimized post-vaccination strategies and preventative measures for sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475973/
https://www.ncbi.nlm.nih.gov/pubmed/34580677
http://dx.doi.org/10.1101/2021.09.17.21263723
work_keys_str_mv AT pettitrowland optimizedpostvaccinationstrategiesandpreventativemeasuresforsarscov2
AT pengbo optimizedpostvaccinationstrategiesandpreventativemeasuresforsarscov2
AT yupatrick optimizedpostvaccinationstrategiesandpreventativemeasuresforsarscov2
AT matospeterg optimizedpostvaccinationstrategiesandpreventativemeasuresforsarscov2
AT greningeralexanderl optimizedpostvaccinationstrategiesandpreventativemeasuresforsarscov2
AT mccashinjulie optimizedpostvaccinationstrategiesandpreventativemeasuresforsarscov2
AT amoschristopherian optimizedpostvaccinationstrategiesandpreventativemeasuresforsarscov2